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Considering	that	noradrenergic	(NAE)	neurons	of	the	locus coeruleus	(LC)	play	significant	
roles	in	the	formation	of	biological	rhythms,	pain,	addictions,	and	mood	disorders,	we	tested	
the	effects	of	acute	intracerebroventricular	microinfusions	of	bupropion,	an	inhibitor	of	NA	
reuptake	used	in	clinics	as	an	antidepressant,	on	background	spike	activity	on	LC	neurons	in	
chloral-hydrate	anesthetized	rats.	Ten	microliters	of	the	solutions	containing	0.001,	0.01,	0.1,	
1.0,	or	10.0	µmol	bupropion	were	infused	during	3	min;	spike	activity	of	single	LC	neurons	
identified	according	 to	 the	known	characteristics	was	 recorded	extracellularly	by	glass	mi-
croelectrodes.	Microinfusions	of	0.01	to	10.0	µmol	bupropion	suppressed	background	spik-
ing	of	the	above	neurons	in	a	dose-dependent	manner.	The	normalized	mean	intensities	and	
durations	of	 inhibition	were	17.3,	 19.4,	 26.3,	 and	41.1%	and	1.4,	 7.1,	 12.4,	 and	18.3	min,	
respectively.	The	smallest	dose	 (0.001	µmol)	was	 ineffective.	 It	 is	assumed	 that	bupropion	
increases	the	NA	level	in	proximity	to	NAE	LC	neurons.	The	actions	of	bupropion	on	other	
cerebral	neuromodulatory	systems	need	further	examination.	Inhibition	of	LC	neuronal	activ-
ity	by	bupropion	can	help	to	explain	some	acute,	chronic,	and	side	effects	of	this	agent	used	
in	clinics	for	correction	of	mood	disorders.	
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INTRODUCTION
The	 noradrenergic	 (NAE)	 neurons	 of	 the	 locus 
coeruleus	 (LC)	 play	 essential	 roles	 in	 the	 control	
of	 important	 biological	 phenomena	 such	 as	 sleep,	
cardiovascular	 control,	 depression,	 etc.	 [1].	 The	
monoamine	 hypothesis	 of	 depression	 genesis	 was	
proposed	 in	 1965;	 as	 was	 assumed,	 monoamines,	
noradrenaline	 (NA)	 in	 particular,	 are	 likely	 to	 be	
the	 key	 elements	 in	 the	 etiology	 and	 progression	 of	
depression.	This	 hypothesis	motivated	 researchers	 to	
elucidate	 the	 roles	 of	 monoamine	 neurotransmitters,	
serotonin	(5-hydroxytryptamine,	5-HT),	noradrenaline	
(NA),	 and	 dopamine	 (DA),	 in	 the	 pathogenesis	 of	
depression.	Further	development	of	the	catecholamine	
hypothesis	 proposed	 that	 depression	 may	 be	 related	
simply	 to	 a	 deficiency	 of	 catecholamines,	 mostly	 of	
NA	[2].	However,	both	elevations	and	reductions	in	the	
level	of	NA	or	its	metabolites	have	been	demonstrated	
in	the	cerebrospinal	fluid	(CSF),	plasma,	and	urine	of	
depressed	 patients,	 and	 this	 made	 controversial	 the	
respective	statements	on	the	involvement	of	NA	in	the	
initiation	of	depression	[3].	
According	 to	 the	 monoamine	 hypothesis	 on	 the	
etiology	of	depression,	the	LC	plays	a	major	role	in	the	
respective	disorders	[4];	the	deficiency	of	monoamines	
in	 the	 brain	 regions	 is	 the	 major	 factor	 for	 the	
development	of	depression,	 and	most	 antidepressant	
drugs	increase	the	synaptic	availability	of	monoamines	
[5-7].	 However,	 convincing	 evidence	 of	 a	 primary	
role	of	dysfunction	of	 the	 specific	monoamine	brain	
systems	 in	 patients	with	major	 depressive	 disorders	
has	not	been	found	[5].	
Although	 the	main	effects	of	antidepressants	were	
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thought	to	be	reflected	in	the	activation	of	LC	neurons,	
studies	of	LC	neuronal	activity	revealed	a	paradoxical	
evidence	 of	 both	 decreased	 density	 of	 neurons	
and	 increased	 tyrosine	 hydroxylase	 activity	 [8,	 9].	
Chronic	 administration	 of	 some	 antidepressants	 can	
decrease	 background	 and	 burst	 evoked	 firing	 of	LC	
neurons	 [10,	11].	Recently,	West	 et	 al.	 reported	 that	
an	antidepressant,	paroxetine,	 increased	LC	neuronal	
activity	in	young	rats	[12];	thus,	it	was	shown	that	the	
effect	of	some	antidepressants	on	LC	neuronal	activity	
may	be	unique.	
As	was	 reported,	acute	systemic	administration	of	
bupropion	in	rats	inhibited	LC-NAE	neuronal	activity.	
This	inhibition	appeared	unrelated	to	a	direct	action	of	
bupropion	on	LC-NAE	neurons	or	 to	 its	modulatory	
action	on	other	neurotransmitters	in	the	brain	regions.	
Metabolites	of	bupropion	can	alter	neuronal	activity	of	
the	above	neurons	[13].	Desipramine,	an	NA	reuptake	
blocker,	 was	 found	 to	 inhibit	 LC	 neuronal	 activity,	
but	the	nature	of	such	inhibitory	effects	exerted	by	its	
metabolites	or	itself	was	not	convincingly	interpreted	
[14].	 In	our	 recent	study,	we	assumed	 that	bupropion	
may	increase	the	activity	in	the	ventral	tegmental	area	
indirectly	via	inhibition	of	GABAergic	neurons	[15].
We	assume	 that	 inhibition	of	LC	neuronal	activity	
by	 bupropion	 is	 provided	 by	 the	 direct	 action	 of	
bupropion	on	NA	receptors	localized	on	the	dendrites	
and/or	 soma	 of	 LC-NAE	 neurons.	 This	 study	 was	
designed	 to	 test	 the	effects	of	 intracerebroventricular	
(ICV)	acute	microinfusions	of	bupropion	on	 impulse	
neuronal	activity	in	the	LC	and	to	evaluate	the	direct/
indirect	nature	of	the	effect	of	this	agent.	
METHODS
Healthy	male	Wistar	rats	(Pasteur	Institute,	Iran;	body	
mass	 250–280	 g)	 were	 used.	 Animals	 were	 housed	
three	in	a	cage	at	a	12	h	light/dark	cycle	(7:00	a.m.	to	
7:00	p.m.)	and	controlled	temperature	(22	±	2°C)	with	
food	and	water	ad libitum.	Animals	were	divided	into	
seven	groups:	control,	sham,	and	five	groups	microin-
fused	with	 solutions	 containing	 different	 amounts	 of	
bupropion	 (n	 =	 6	 to	 12	 rats	 in	 each	 group).	The	 rats	
were	 anesthetized	 with	 chloral	 hydrate	 (400	 mg/kg,	
i.p.;	the	booster	dose	was	about	10-15%	of	the	initial	
dose)	and	secured	in	a	stereotaxic	instrument	(Stoelt-
ing,	USA).	The	body	temperature	was	monitored	con-
tinuously	 and	 maintained	 at	 ~37°C	 throughout	 the	
experiment.	The	bregma	and	interaural	stereotaxic	co-
ordinates	were	measured	for	each	rat,	and	the	location	
of	 the	 opening	 for	 LC	 recording	was	 determined	 ac-
cording	to	the	rat	stereotaxic	brain	atlas	[16].	
Single	 unit	 spike	 activity	 was	 recorded	 from	 LC	
neurons	as	described	previously	[17].	Briefly,	after	an-
esthesia	and	opening	of	 the	skull,	 a	glass	microelec-
trode	 (in vitro	 impedance	3-6	MΩ)	 filled	with	 a	 2%	
solution	of	Pontamine	Sky	Blue	in	0.5	M	sodium	acet- 
ate	was	inserted	in	the	brain	into	the	region	of	LC	lo-
calization	 (Bregma	–9.84,	ML	1.35,	and	DV	6.8	mm	
with	respect	to	the	bregma	zero-zero	plane)	until	sin-
gle	neuronal	activity	could	be	clearly	detected.	For	all	
neuronal	recordings,	the	criteria	described	earlier	[18-
21]	were	 taken	 into	account.	These	criteria	were	 the	
following;	(i)	long-lasting	positive-negative	waveform	
with	 a	 notch,	 (ii)	 biphasic	 excitation-inhibition	 re-
sponses	to	contralateral	hind	paw	pinch,	and	(iii)	regu-
lar	background	activity	with	a	relatively	low	firing	rate	
(0.5-5.0	sec–1).	The	units	satisfying	the	mentioned	cri-
teria	were	recorded	in	the	case	of	stable	amplitude	and	
firing	 rate.	The	 recorded	activity	was	 filtered	 (band-
pass	300-3000	Hz),	amplified,	digitized,	and	addressed	
to	a	PC	computer	 (Electromodule	3111	data	acquisi-
tion	system,	Http://www.sciencebeam.com/).	Digitized	
data	were	displayed	on	an	oscilloscope	using	Neuro-
Comet	software	(Http://www.sciencebeam.com).	This	
software	was	also	used	for	window	discrimination	of	
spikes	and	analysis	of	the	activity.	Peri-stimulus	time	
histograms	(PSTHs)	for	single	units	were	plotted	with	
1-msec-long	bins.	Sensitization	or	desensitization	of	
the	recorded	units	was	tested	by	contralateral	hind	paw	
compression.	All	units	with	no	respective	shifts	were	
included	 in	 the	analysis.	Frequency	graphs	were	also	
plotted	for	estimation	of	the	firing	rate	stability.	
The	 PSTHs	 extracted	 on-line	 or	 off-line	 were	
checked	again	by	a	blind-control	person.	Samples	of	
spiking	used	for	plotting	PSTHs	and	current	frequen-
cy	graphs	were	5	min	long.	In	each	record,	the	spiking	
stability	was	estimated	within	a	5-min-long	 interval,	
and	 a	 subsequent	 10-min-long	 interval	was	used	 for	
baseline	estimation.	Forty-min-long	 recordings	were	
used	for	assessing	possible	effects	of	 infusions	of	ar-
tificial	cerebrospinal	fluid	(ACSF)	or	the	drug	(bupro-
pion),	with	cut-off	on	the	60th	min.	
For	bupropion	 infusion,	a	30-gauge	stainless	 steel	
needle	was	connected	to	a	10	µl	Hamilton	syringe	by	a	
polyethylene	tube.	The	needle	was	stereotaxically	in-
serted	into	the	right	lateral	ventricle.	The	drug	vehicle	
(ACSF)	or	 solutions	containing	different	amounts	of	
bupropion	were	injected	by	a	microsyringe	pump.	The	
volumes	of	all	injections	were	10	µl,	and	the	duration	
of	 infusion	was	3	min.	Concentrations	of	 bupropion	
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in	the	solutions	used	for	microinfusions	were	0.0001,	
0.001,	0.01,	0.1,	and	1.0	M;	 thus,	 the	amounts	of	 in-
fused	bupropion,	considering	the	volume	of	infusions	
(10	µl),	were	0.001,	0.01,	0.1,	1.0,	and	10.0	µmol,	re-
spectively.
After	the	experiments,	all	animals	were	deeply	anes-
thetized	 and	 perfused	with	 10%	 phosphate-buffered	
formalin	solution.	The	brains	were	removed	and	fixed	
in	 the	 perfusion	 solution.	Coronal	 40-µm-thick	 sec-
tions	were	 prepared	 on	 a	microtome	 and	 stained	 by	
Fast	Cresyl	Violet.	The	trajectory	path	and	location	of	
the	infusion	cannula	tip	were	verified	under	a	light	mi-
croscope.	The	 rats	with	unsuccessful	 injections	were	
excluded	from	the	analysis.
Drugs,	chemicals,	and	equipment	used	in	our	study	
included	 bupropion,	 formalin,	 Pontamine	 Sky	Blue,	
Fast	 Cresyl	Violet,	 chloral	 hydrate	 (Sigma-Aldrich,	
USA),	 sodium	 acetate	 and	 sodium	 chloride	 (Merck,	
Germany),	 polyethylene	 microtubes	 (A-M	 system,	
USA),	and	Hamilton	microsyringes	 (Hamilton	Bona-
duz	AG,	Switzerland).	
Numerical	data	of	the	firing	rate	of	single	units	were	
analyzed	using	one-way	analysis	of	variance	(ANOVA).	 
Analysis	of	 the	 effect	 of	different	doses	of	 the	drug	
was	carried	out	using	ANOVA	and	 the	Tukey’s	post-
hoc	test.	P	<	0.05	indicated	the	least	statistical	signifi-
cance	 in	 intergroup	comparisons.	Numerical	data	are	
shown	below	as	means	±	s.d.	
RESULTS
An	example	of	the	typical	LC	neuronal	spike	is	shown	
in	Fig.	1	A;	the	upper	and	lower	levels	of	window	dis-
crimination	 are	 also	 seen.	The	 absolute	 amplitude	 of	
the	 extracellularly	 recorded	 single	 unit	 spikes	 varied	
between	40	and	250	µV.	A	brief	pinch	of	the	contralat-
eral	paw	served	as	the	test	for	verifying	that	the	neu-
ron	belongs	to	the	LC	nucleus.	The	paw	pinch	elicited	
a	 burst	 of	 activity	 in	 single	 units	 in	 chloral	 hydrate-
anesthetized	rats;	such	bursts	were	accompanied	by	a	
period	of	after-inhibition	(Fig.	1	B).	A	greater	pressure	
could	elicit	a	more	significant	increase	in	the	burst	fir-
ing	rate	with	no	sensitization.
Figure	 2A	 is	 a	 typical	 graph	 for	 the	 firing	 rate	 of	
an	 LC	 neuron	 in	 an	 anesthetized	 rat	 of	 the	 control	
group.	The	neuron	firing	rate	was,	in	this	case,	1.88	±	 
±	0.05	sec–1.	As	can	be	 seen,	variations	of	 the	 firing	
rate	of	background	activity	are	minimum;	the	station-
arity	of	 this	 activity	 is	 a	 typical	 feature	of	LC	NAE	
neurons.	For	 testing	of	 the	microinfusion	volume	ef-
fect	on	LC	neuronal	activity,	the	drug	vehicle	(ACSF)	
was	microinjected	 in	 the	 sham	group	 (10	µl/3	min).	
Figure	2B	shows	a	typical	example	of	the	neuronal	fir-
ing	rate	observed	under	such	conditions.	In	 this	sam-
ple,	the	mean	firing	rate	within	the	pre-microinfusion	
period	(minutes	1	to	10)	was	1.90	±	0.04	sec–1,	while	
that	within	 the	 post-microinfusion	 interval	 (minutes	
14	to	45)	was	1.87	±	0.04	sec–1.	Analysis	of	the	firing	
rates	within	the	pre-	and	post-microinfusion	of	ACSF	
showed	that	 there	was	no	statistically	significant	dif-
ference	between	these	values	(t-test,	P	=	0.31).	Thus,	
microinjections	of	10	µl	of	ASCF	exerted	negligible	
effects	on	background	firing	of	LC	neurons.	
In	the	control	group	(n	=	8),	24	LC	neurons	were	re-
corded,	and	26	units	were	recorded	in	the	sham	group	
(n	=	7).	The	average	firing	rate	of	control-group	neu-
rons	was	2.54	±	1.11sec–1,	while	that	in	the	sham	group	
was	2.65	±	1.26	sec–1.	In	all	records,	there	was	no	sig-
nificant	difference	between	the	pre-microinfusion	and	
1 msec
50 µV
A
B
F i g. 1.	Pattern	of	spike	activity	recorded	from	locus coeruleus	(LC)	neurons.	A)	Waveform	of	a	typical	extracellularly	recorded	single	unit	
spike	of	an	LC	neuron.	A	notch	on	the	ascending	spike	limb	is	seen;	limits	for	window	discrimination	by	NeuroComet	software	are	shown.	
B)	Typical	response	of	an	LC	neuron	to	a	brief	pinch	of	the	contralateral	paw.	Background	firing	of	this	neuron	was	low-frequency	and	
regular.	The	sensory-evoked	response	was	followed	by	a	silence	period	(post-stimulus	inhibition).	
Р и с. 1.	Патерн	імпульсної	активності,	що	відводиться	від	нейронів	блакитної	плями	(LC).	
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post-microinfusion	periods.	
Figure	3	shows	the	effects	of	different	ICV-infused	
bupropion	doses	(0.001,	0.01,	0.1,	1.0,	and	10.0	µmol)	
on	 the	background	 firing	 rate	of	 five	LC	neurons.	 It	
is	obvious	 that	bupropion-induced	effects	are	clearly	
dose-dependent.	Doses	of	0.01	to	10.0	µmol	provided	
noticeable	 inhibition	of	LC	activity,	while	 there	was	
no	significant	inhibitory	effect	of	the	lowest	bupropion	
dose	(0.001	µmol).	
The	significant	dependence	of	 the	 intensity	of	bu-
propion-induced	 suppression	of	background	 impulse	
activity	generated	by	LC	NAE	neurons	and	 the	 time	
course	of	this	inhibition	are	more	clearly	visible	on	a	
graph	of	normalized	changes	in	this	activity	for	the	en-
tire	examined	group.	The	effects	of	infusions	of	0.001,	
0.01,	0.1,	1.0,	and	10.0	µmol	bupropion	were	exam-
ined	 on	 22,	 28,	 23,	 29,	 and	 34	LC	 neurons,	 respec-
tively.	The	mean	normalized	intensities	of	decreases	in	
the	rate	of	background	firing	were	1.41	±	0.12,	7.14	±	 
±	4.85,	12.40	±	3.11,	and	18.30	±	5.45%	for	the	doses	
of	infused	bupropion	of	0.01,	0.1,	1.0,	and	10.0	µmol,	
respectively	(Fig.	4,	2-5).	In	all	cases,	the	firing	rates	
of	 LC	 neurons	 within	 the	 pre-microinfusion	 period	
were	taken	as	100%.	The	maxima	of	bupropion-evoked	
inhibition	of	 spiking	were	also	shifted	with	 increase	
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F i g. 2.	Frequency	graphs	of	background	activity	generated	by	locus 
coeruleus	 (LC)	neurons.	A)	Graph	illustrating	a	stationary	pattern	
of	background	spiking	of	an	LC	neuron.	B)	Graph	illustrating	the	
absence	of	a	significant	effect	of	intracerebroventricular	infusion	of	
the	vehicle	(ASCF)	on	background	activity	of	an	LC	neuron.	The	
moment	of	beginning	 (arrow)	and	duration	of	 infusion	are	shown	
above	the	graph	and	on	the	abscissa,	respectively.	
Р и с. 2.	 Графіки	 частоти	 фонової	 активності,	 генерованої	
нейронами	блакитної	плями	(LC).
F i g. 3.	Effects	of	different	doses	of	ICV-microinfused	bupropion	
(0.001,	 0.01,	 0.1,	 1.0,	 and	 10.0	 µmol,	 1-5,	 respectively)	 on	
background	firing	of	five	LC	neurons	(1-5).	The	time	of	infusion	is	
indicated	on	the	abscissa.	
Р и с. 3.	 Впливи	 внутрішньошлуночкових	 мікроінфузій	
різних	доз	бупропіону	(0.001,	0.01,	0.1,	1.0	або	10	мкмоль,	1–5	
відповідно;	10	мкл/3	хв)	на	фонові	розряди	п’яти	нейронів	LC 
(1–5).
Fig. 4.	 Averaged	 normalized	 bupropion-induced	 changes,	 %,	 in	
the	firing	rate	of	 the	examined	LC	neurons.	The	mean	firing	rates	
within	 the	 pre-infusion	 period	were	 taken	 in	 each	 case	 as	 100%.	
Other	indications	are	similar	to	those	in	Fig.	3.	
Р и с. 4.	 Усереднені	 по	 групі	 нормовані	 зміни	 (%)	 частоти	
розряду	 досліджених	 нейронів	 LC,	 викликані	 інфузіями	
бупропіону	
in	the	dose	of	the	infused	drug,	and	the	total	duration	
of	 inhibition	 increased	 (Fig.	4).	The	duration	of	sup-
pression	of	 impulsation	was	 calculated	by	 repeated-
measure	ANOVA	for	determination	of	the	differences	
between	points.	The	averaged	durations	of	 such	sup-
pression	at	the	above-mentioned	bupropion	doses	were	
1.41	±	1.20,	 7.14	±	4.85,	 12.40	±	3.11,	 and	18.00	±	 
±	4.45	min,	 respectively.	These	data	are	summarized	
in	the	diagrams	of	Fig.	5.	The	smallest	infused	bupro-
pion	dose	(0.001	µmol)	provided	no	significant	effect	
on	LC	neuronal	firing	rate	(P	=	0.23).	
DISCUSSION 
Our	 electrophysiological	 data	 demonstrated	 that	
min
min
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acute	 ICV	 microinfusions	 of	 bupropion,	 an	 NA	
reuptake	 inhibitor	 frequently	qualified	 as	 an	 atypical	
antidepressant,	are	capable	of	significantly	suppressing	
background	 neuronal	 activities	 of	 single	 LC	 neurons	
in	 a	 clear	 dose-dependent	 manner.	 No	 dramatic	
sensitization	 or	 desensitization	 in	 the	 influence	 of	
bupropion	on	LC	neurons	was	observed,	and	this	agent	
could	 inhibit	 the	above	background	neuronal	activity	
for	a	few	minutes.	
Hypotheses 	 on	 the	 mechanisms	 by	 which	
antidepressants,	 such	 as	 bupropion,	 can	 produce	
inhibition	of	LC	neuronal	 activity	 are	 controversial.	
The	main	suggested	mechanism	for	 inhibition	of	LC	
neurons	 by	 antidepressants	 is	 the	 involvement	 of	
NA	reuptake	blocking	 in	 the	vicinity	of	 the	dendritic	
tree	 and/or	 soma	 of	 these	 neurons.	Blocking	 of	 this	
reuptake	 process	 by	 bupropion	 is	 consistent	 with	 a	
strong	inhibitory	action	on	LC	firing	that	is	exerted	via	
stimulation	of	 somatodendritic	alpha-2	NA	receptors	
localized	 on	 LC	 neurons.	 The	 elevated	NA	 level	 in	
close	proximity	to	somatodendritic	synapses	results	in	
more	 intense	binding	of	NA	to	alpha-2	 receptors	and	
provides	hyperpolarization	of	LC	neurons.	This	effect	
can	be	mimicked	by	clonidine	(an	alpha	2-adrenoceptor	
agonist)	 [22-24].	 Not	 only	 NA	 reuptake	 inhibitors,	
but	also	other	inhibitors	influencing	biogenic	amines,	
in	 particular	 5-HT	 reuptake	 inhibitors,	 can	 suppress	
spiking	 of	 LC	 neurons.	 The	 respective	 findings	
revealed	 that	 serotonergic	 receptors	are	 localized	on	
the	 LC	 cell	 bodies,	 and	 the	 action	 of	 5-HT	 within	
the	 regions	 adjacent	 to	 these	 receptors	 inhibits	 LC	
activation	[25].	Therefore,	any	agent	that	can	increase	
the	 NA	 concentration	 in	 the	 synaptic	 environment	
can	 inhibit	LC	 impulse	activity.	Monoamine	oxidase	
(MAO)	 inhibitors	 can	 also	 suppress	 spiking	 of	 LC	
neurons	by	increasing	the	NA	level	[26].	
Observations	made	 in	 our	 study	 on	 the	 inhibitory	
action	 of	 acute	 ICV	 infusions	 of	 bupropion	 are	
consistent	with	what	 other	 investigators	 found	 after	
administration	of	antidepressant	drugs	[27-29].	There	
were	 reports,	 however,	 that	 chronic	 administrations	
of	some	antidepressants	did	not	decrease	background	
or	 sensory-evoked	 LC	 neuronal	 activity	 due	 to	
manifestations	of	tolerance	under	conditions	of	chronic	
action	of	 these	drugs	 [28,	30,	31].	 It	 should	be	 taken	
into	 account	 that	 tolerance	 could	 not	 significantly	
develop	 in	 our	 experiments	 where	 acute	 action	 of	
bupropion	was	tested.	
The	involvement	of	NA	receptors	of	LC	neurons	in	
the	pathogenesis	of	major	depression	 (MD)	has	been	
studied in post mortem	 cases.	 Based	 on	 the	 data	 of	
many	 researches,	 an	 abnormal	 state	 of	 the	 central	
NAE	 system	 was	 proposed	 to	 play	 an	 important	
role	 in	 the	pathophysiology	of	 this	 disease.	Alpha-2	
adrenoreceptors	 throughout	 the	 LC	 were	 found	
to	 be	 significantly	 elevated	 in	 patients	 suffering	
from	MD	compared	 to	 the	matched	 control	 subjects	
[32].	 Increased	 levels	 of	 tyrosine	 hydroxylase	 and	
decreased	 levels	of	 the	NA	 transporter	 (NAT)	 imply	
NA	deficiency	in	the	LC	related	to	MD.	The	NAT	is	a	
membrane	protein	 responsible	 for	 termination	of	 the	
action	of	synaptic	NA	and	is	a	site	of	action	for	many	
drugs	used	to	treat	MD	[33].
The	 mechanism	 of	 reduction	 of	 the	 LC	 neuronal	
firing	rate	due	to	acute	ICV	infusions	of	bupropion	is	
not	 fully	 understood.	There	 is	well-known	 evidence	
that	 the	 effect	 of	 bupropion	 (a	 rapid	 and	 significant	
drop	 in	 the	 firing	 rate	 of	 LC	 cells)	 is	 antagonized	
by	 yohimbine	 and	 piperoxane	 (alpha-2	 adrenergic	
antagonists),	 implying	 that	 there	 is	 ultimately	
activation	of	 alpha-2	 receptors	 in	 the	 rat	 brain	 [34].	
An	 indirect	mechanism	of	bupropion	 for	suppression	
of	 LC	 firing	 does	 not	 completely	 explain	 the	 effect	
of	 this	drug	on	LC	neurons	because	 inhibition	of	NA	
uptake can be demonstrated in vivo	 only	 at	 tenfold-
higher	doses	 [35].	At	 the	same	 time,	our	 findings	on	
the	action	of	bupropion	are	consistent	with	what	other	
researchers	 reported	 after	 acute	 administration	 of	
antidepressant	drugs	[27-29,	36,	37].
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Fig. 5.	Dose	 dependence	 of	 the	 effects	 of	 ICV	microinfusions	 of	
bupropion	 on	 the	 duration	 (filled	 columns,	 min)	 and	 maximum	
inhibition	 (open	 columns,	 %)	 of	 LC	 background	 spike	 neuronal	
activity.	The	 duration	 of	 inhibition	 of	 the	 activity	was	 calculated	
by	repeated-measure	ANOVA	for	determination	of	 the	differences	
between	 points.	 The	 maximum	 inhibition	 was	 estimated	 as	 the	
average	 in	 the	 experimental	 groups.	The	mean	firing	 rates	within	
the	pre-infusion	period	was	assumed	as	100%.	Asterisks,	crosses,	
and	diagonal	crosses	indicate	cases	with	P	<	0.05	in	comparison	to	
groups	treated	with	10.0,	1.0,	and	0.1	µmol,	respectively.	ANOVA	
with	post-hoc	Tukey’s	protected	t-test	was	used.
Р и с. 5.	Дозозалежність	характеристик	гальмування	(тривалості,	
хв,	 та	 максимальної	 інтенсивності	 гальмування,	 %),	 фонової	
імпульсної	активності	(чорні	та	білі	стовпчики	відповідно)	під	
впливом	мікроінфузій	бупропіону.
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The	acute	antidepressant	effect	of	bupropion	is	more	
closely	 associated	with	 its	 action	 on	 the	 firing	 rate	
of	NAE	LC	neurons	 than	with	 its	effect	on	midbrain	
mesolimbic	 dompaminergic	 neurons.	 These	 results	
confirm	previous	findings	[10,	11,	38].	
Thus,	 we	 found	 that	 ICV	 microinfusions	 of	 the	
atypical	antidepressant	bupropion	 inhibit	background	
impulse	 activity	 of	 LC-NAE	 neurons	 in	 chloral	
hydrate-anesthetized	rats	in	a	dose-dependent	manner.	
A	 detailed	 understanding	 of	 the	 pharmacological	
properties	 of	 bupropion	 should	 help	 to	 establish	
the	 true	 efficacy	 of	 its	 action	 on	 NA	 uptake.	
Potent	 interactions	 of	 bupropion	 with	 cholinergic,	
histaminergic, 	 serotonergic, 	 and	 dopaminergic	
systems	in	the	brain	should	be	examined	for	adequate	
interpretation	of	 the	effects	of	 this	drug.	At	 the	same	
time,	our	data	add	some	information	helping	to	explain	
acute,	chronic,	and	side	effects	of	bupropion	used	 in	
clinics	for	correction	of	mood	disorders.	
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Резюме
Враховуючи,	 що	 норадренергічні	 (НАЕ)	 нейрони	 бла-
китної	 плями	 (locus coeruleus	 –	 LC)	 відіграють	 істотну	
роль	 у	 формуванні	 біологічних	 ритмів,	 болю,	 фармако-
логічних	 залежностей	 та	 розладів	 настрою,	ми	 тестували	
впливи	 гострих	 інтрацеребровентрикулярних	 мікроінфу-
зій	 антидепресанта	 бупропіону	 на	 фонову	 активність	 не-
йронів	 LC	 у	 щурів.	 Уводили	 10	 мкл	 (тривалість	 інфузій	 
3	хв)	розчинів,	що	вміщували	різні	дози	 (0.001,	0.01,	 0.1,	
1.0	 або	 10.0	 мкмоль)	 бупропіону	 –	 інгібітора	 зворотно-
го	 захоплення	норадреналіну,	що	використовується	 в	 клі-
ніці	 як	 антидепресант.	 Імпульсну	 активність	 поодиноких	
нейронів	LC	відводили	позаклітинно	скляними	мікроелек-
тродами.	Мікроінфузії	0.01–10.0	мкмоль	бупропіону	дозоза-
лежно	пригнічували	фонову	імпульсацію	цих	нейронів.	Се-
редня	нормована	 інтенсивність	та	тривалість	гальмування	
складали	в	даних	випадках	17.3,	19.4,	26.3	 і	41.1	%	та	1.4,	
7.1,	 12.4	 і	 18.3	хв	відповідно.	Найменша	доза	бупропіону	 
(0.001	мкмоль)	була	неефективною.	Вважається,	що	бупро-
піон	зумовлює	підвищення	рівнів	цього	катехоламіну	в	зоні	
розташування	НАЕ-нейронів	LC.	 Взаємодія	 бупропіону	 з	
іншими	центральними	нейромодуляторними	системами	по-
требує	подальшого	вивчення.	Факт	гальмування	нейронної	
імпульсної	активності	в	LC	під	впливом	бупропіону	може	
сприяти	 інтерпретації	особливостей	гострих	та	хронічних	
впливів	цього	агента	та	його	побічних	ефектів	при	застосу-
ванні	в	клініці	для	корекції	розладів	настрою.
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